Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195359 | 0.90 | ATAD2 (0.38) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL10195291 | 0.90 | EPHX2 (0.34) | EPHX2ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL10195210 | 0.89 | KMT2A (0.35) | EPHX2MAPTRAB9ALTA4HCTSD | |
| SCHEMBL10195209 | 0.88 | CYP1A2 (0.42) | EPHX2SMN1; SMN2LTA4HCTSD | |
| SCHEMBL10195366 | 0.86 | EPHX2 (0.45) | EPHX2MAPT | |
| SCHEMBL10195365 | 0.86 | DYRK1A (0.39) | EPHX2MAPTSMN1; SMN2GAARAB9A | |
| SCHEMBL16351646 | 0.86 | KMT2A (0.39) | ALDH1A1MAPTSMN1; SMN2RAB9ATDP1 | |
| SCHEMBL10195363 | 0.84 | NPC1 (0.38) | EPHX2ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL10195360 | 0.84 | L3MBTL1 (0.37) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL10195386 | 0.83 | CTSD (0.34) | EPHX2SMN1; SMN2GAALTA4HCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | EPHX2 154/4885ALDH1A1 14/4885MAPT 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.